Head to head
Semaglutide vs Retatrutide
Two compounds, one grading system.
On human evidence, Semaglutide currently leads: fda approved versus well researched.
01
At a glance
SemaglutideFDA approved
GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.
17,774publications
640RCTs
RetatrutideWell researched
Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.
927publications
18RCTs
02
Side by side
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Goal | Metabolic & fat loss | Metabolic & fat loss |
| Evidence | FDA approved | Well researched |
| Publications | 17,774 | 927 |
| Randomised trials | 640 | 18 |
| Sport (WADA) | not listed | S0 — prohibited |
| US compounding | — | — |
03
Claims vs data
Semaglutide — claims vs data
| Produces clinically meaningful weight loss | supported |
| Improves glycaemic control in type 2 diabetes | supported |
| Free of side effects | overreach |
Retatrutide — claims vs data
| Largest weight loss of any trialled agent to date | partially true |
| Approved and available | overreach |